Study of antitumor effects of human placenta hydrolysate on PC-3, OAW-42, BT-474 cell cultures
Open Access
- 16 April 2024
- journal article
- research article
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (3) , 266-272
Abstract
Aim. To investigate the antitumor effects of human placenta hydrolysate (HPH) peptides on three hormone-dependent human cell lines: prostate adenocarcinoma, breast carcinoma, and ovarian cancer by metabolic analysis of cell cultures. Materials and methods. The effect of HPH on tumor and control tumor cell lines was evaluated. Study stages: (A) de novo peptide sequencing by collision-induced dissociation mass spectrometry; (B) detection of peptides with anti-tumor properties; (C) expert analysis of the obtained lists of peptides. Results. Dose-dependent cytotoxic effects of HPH on three tumor cell lines are shown: PC-3 (human prostate adenocarcinomas), OAW-42 (human ovarian cancer), BT-474 (human breast carcinomas), and IC50 constants (1.3–2.8 mg/ml) were obtained. The analysis of the HPH peptide fraction showed more than 70 peptides with antitumor properties in the composition of this HPH, including kinase inhibitors: mitogen-activated protein kinases, kappa-bi nuclear factor inhibitor kinase, AKT serine/threonine kinase 1, protein kinase C zeta, interleukin-1 receptor-associated kinase 4 and cyclin-dependent kinase 1. Conclusion. The results of the study indicate not only the oncological safety of the HPH used in therapy but also the mild antitumor effects of this HPH at high concentrations.Keywords
This publication has 29 references indexed in Scilit:
- Human placental extract ameliorates methotrexate-induced hepatotoxicity in rats via regulating antioxidative and anti-inflammatory responsesCancer Chemotherapy and Pharmacology, 2021
- Synthesis and antihypotensive properties of 2-amino-2-thiazoline analogues with enhanced lipophilicityMendeleev Communications, 2018
- TG and VLDL cholesterol activate NLRP1 inflammasome by Nuclear Factor-κB in endothelial cellsInternational Journal of Cardiology, 2016
- Functional assessment of the mutational effects of human IRAK4 and MyD88 genesMolecular Immunology, 2014
- An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteomeJournal of Proteomics, 2014
- Toward a Comprehensive Characterization of a Human Cancer Cell PhosphoproteomeJournal of Proteome Research, 2012
- Two Human MYD88 Variants, S34Y and R98C, Interfere with MyD88-IRAK4-Myddosome AssemblyJournal of Biological Chemistry, 2011
- Use of Inhibitors in the Study of MAP Kinases2010
- Kinase-Selective Enrichment Enables Quantitative Phosphoproteomics of the Kinome across the Cell CycleMolecular Cell, 2008
- Multiple nuclear factors interact with the immunoglobulin enhancer sequencesCell, 1986